Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell Carcinoma

Video

In Partnership With:

Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a second-line therapy for metastatic renal cell carcinoma.

Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a frontline therapy for metastatic renal cell carcinoma (mRCC).

The randomized dose titration study enrolled approximately 200 patients with mRCC. Patients were first treated with the standard dose at 5 mg twice daily for 30 days. Criteria to be randomized to receive an increased dosage included a lack of incidence of toxicity and/or hypertension.

Patients were then randomized to an increased dose of axitinib versus placebo, which was the standard dose. A 20% advantage in response rate was demonstrated in the titration arm. Progression-free survival and overall survival was favored in the titration arm, but was not found to be statistically significant. Researchers determined that dose titration needs to be carefully done so as to not harm patients with higher levels of toxicities.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,